LLY and PFE Related Headlines
Go Back- Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight
- Large cap pharma defensive AI winner, says RBC as it backs Lilly & AbbVie
- Barclays launches U.S. biopharma coverage with four preferred picks
- Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight
- Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) | DelveInsight
- Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight
- Eli Lilly, Pfizer, AbbVie drugs targeted in third Medicare price talks
- Trump to announce prescription drug price agreements
- Bernstein on IRA pricing: $245 really is the floor
- US Pausing Pharma Duties While Negotiations Ongoing - Politico
- Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
- FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
- Fact Sheet: President Donald J. Trump Announces First Deal to Bring Most-Favored-Nation Pricing to American Patients
- Trump on deal with Pfizer: we're going to be paying the lowest price, other drugmakers will commit in coming weeks
- Bernstein on AmericasMedicines.com: 'The Noise Starts, But Not (Yet) from Trump'
- Raymond James Comments on FDA and HHS Reforms for DTC Pharma Advertising
- White House: Trump took action on pharma Thursday, sent letters to CEOs
- Jefferies: 'We highlight multiple de-risked or commercial-stage names that we think have promising M&A potential'
LLY and PFE Related Press Releases
Go Back- Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight
- Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight
- Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) | DelveInsight
- Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight
